10,444 Shares in Five Prime Therapeutics Inc (FPRX) Purchased by Xact Kapitalforvaltning AB

Xact Kapitalforvaltning AB purchased a new position in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,444 shares of the biotechnology company’s stock, valued at approximately $145,000.

Other large investors have also modified their holdings of the company. Northern Trust Corp increased its holdings in shares of Five Prime Therapeutics by 14.5% during the 1st quarter. Northern Trust Corp now owns 370,040 shares of the biotechnology company’s stock valued at $6,357,000 after purchasing an additional 46,742 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Five Prime Therapeutics by 6.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,041,750 shares of the biotechnology company’s stock worth $17,897,000 after acquiring an additional 67,474 shares during the period. UBS Group AG increased its stake in Five Prime Therapeutics by 773.8% during the first quarter. UBS Group AG now owns 98,653 shares of the biotechnology company’s stock worth $1,695,000 after purchasing an additional 87,363 shares during the period. The Manufacturers Life Insurance Company increased its stake in Five Prime Therapeutics by 17.8% during the first quarter. The Manufacturers Life Insurance Company now owns 25,032 shares of the biotechnology company’s stock worth $430,000 after purchasing an additional 3,782 shares during the period. Finally, California State Teachers Retirement System grew its position in shares of Five Prime Therapeutics by 16.9% during the first quarter. California State Teachers Retirement System now owns 50,093 shares of the biotechnology company’s stock worth $861,000 after buying an additional 7,238 shares in the last quarter. Institutional investors own 86.40% of the company’s stock.

FPRX has been the subject of several research analyst reports. Citigroup decreased their price objective on Five Prime Therapeutics from $60.00 to $44.00 and set a “buy” rating for the company in a report on Monday, August 20th. BidaskClub cut Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. Wedbush increased their price objective on Five Prime Therapeutics from $17.00 to $19.00 and gave the company a “hold” rating in a research note on Friday, August 10th. Wells Fargo & Co decreased their price target on Five Prime Therapeutics from $58.00 to $35.00 and set an “outperform” rating on the stock in a research note on Thursday, August 9th. Finally, Leerink Swann initiated coverage on Five Prime Therapeutics in a research note on Thursday, September 13th. They issued an “outperform” rating and a $24.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the stock. Five Prime Therapeutics currently has a consensus rating of “Hold” and an average target price of $29.67.

Five Prime Therapeutics stock opened at $11.13 on Thursday. The stock has a market capitalization of $430.86 million, a PE ratio of -2.07 and a beta of 3.23. Five Prime Therapeutics Inc has a 12 month low of $10.35 and a 12 month high of $33.10.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). The firm had revenue of $5.77 million during the quarter, compared to analysts’ expectations of $7.45 million. Five Prime Therapeutics had a negative return on equity of 40.73% and a negative net margin of 221.67%. As a group, equities research analysts anticipate that Five Prime Therapeutics Inc will post -4.02 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.wkrb13.com/2018/11/08/10444-shares-in-five-prime-therapeutics-inc-fprx-purchased-by-xact-kapitalforvaltning-ab.html.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Featured Article: Why is the conference call important?

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply